Recursion
Recursion (Recursion Pharmaceuticals) is a clinical-stage TechBio company decoding biology to improve lives. Its Recursion OS platform unites large-scale automated wet-lab experimentation with AI and high-performance computing to discover and develop novel medicines, focused on oncology and rare diseases. The company has generated over 50 petabytes of proprietary biological and chemical data and operates BioHive-2, one of the pharmaceutical industry's most powerful supercomputers, built with NVIDIA. Headquartered in Salt Lake City with offices in Montreal, New York, London and Oxford, it is publicly traded on Nasdaq (RXRX) and merged with Exscientia in 2024.
Public Company
Recursion is publicly traded
IPO'd on April 16, 2021
This company is no longer available on our private secondary market. Shares can be traded publicly under RXRX.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2013
Employees
501–1,000
Total Funding
$437.65M
5 rounds
Last Private Valuation
$0.65B
September 2020
Funding
Total raised $437.65M across 5 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-21-2026
Latest Round
Type
Series C
Date
July 15, 2019
Amount
$121M
Valuation
$0.65B
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| September 2020 | Series D | $239M | — | Leaps by Bayer |
| July 15, 2019 | Series C | $121M | $0.65B | Scottish Mortgage Investment Trust |
| October 3, 2017 | Series B | $60M | — | Data Collective |
Leadership
Najat Khan
Chief Executive Officer & President
Christopher Gibson
Co-Founder & Chair of the Board
Ben Taylor
Chief Financial Officer & President, Recursion UK
David Hallett
Chief Scientific Officer
Competitors
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Schrodinger
Public physics-based and AI-enabled computational drug discovery platform competing with Recursion in AI-driven small molecule design.
Insitro
Private machine-learning-driven drug discovery and development company combining in vitro cellular data with human clinical data, focused on metabolism, oncology, and neuroscience.
Insilico Medicine
Generative AI drug discovery company developing therapeutics across fibrosis, oncology, and aging using its Pharma.AI platform.
BenevolentAI
AI-driven drug discovery company applying its Knowledge Graph and reasoning platform across multiple therapeutic areas.
Valo Health
Private technology-enabled drug discovery and development company using its Opal Computational Platform combining human data with AI.
XtalPi
AI and quantum-physics-based drug discovery and intelligent automation company offering R&D services and platforms to pharma partners.
Recursion Investment FAQ
Recursion FAQ
Yes, Recursion is publicly traded under the ticker symbol RXRX on the NASDAQ. The company went public in April 16, 2021.
Recursion trades under the ticker symbol RXRX on the NASDAQ. It began trading in April 16, 2021.
Recursion (RXRX on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker RXRX to place an order.
Recursion went public in April 16, 2021 via ipo, with an offering valuation of approximately $0.65B. Recursion Pharmaceuticals completed its IPO on the Nasdaq Global Select Market under the ticker RXRX on April 16, 2021, pricing at $18.00 per share and raising approximately $501.8 million in gross proceeds (including the underwriters' over-allotment). The company has remained publicly traded and significantly expanded its operations through its all-stock acquisition of Exscientia, which closed November 20, 2024.
Recursion raised $437.65M across 5 disclosed funding rounds prior to its public listing.
Recursion was founded by Christopher Gibson in 2013.
Recursion is headquartered in Salt Lake City, Utah, United States.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.